Software enhances visualization of dense breasts
OpView image processing software reconstructs breast images obtained from full-field digital mammography, as well as ultrasound and MRI, to bring clarity to challenging breast scans. The software, unveiled Sunday at the RSNA meeting by Siemens Medical Solutions, will assist interpretation of lesions in dense breasts and microcalcifications, according to the company.
OpView image processing software reconstructs breast images obtained from full-field digital mammography, as well as ultrasound and MRI, to bring clarity to challenging breast scans. The software, unveiled Sunday at the RSNA meeting by Siemens Medical Solutions, will assist interpretation of lesions in dense breasts and microcalcifications, according to the company.
Running in concert with visualization features built into Siemens' syngo-based workstations, OpView can be used to adjust the display of images to concentrate on areas of high interest, such as the borders of the breast and subtle masses, or to adjust brightness and contrast for optimal display of images.
The software decreases the quantum and electronic noise from x-rays that can interfere with the evaluation of suspicious lesions, particularly abnormalities that are low in contrast. An edge enhancement feature enhances high frequencies in an image to increase the visibility of structures such as microcalcifications.
In addition to the multimodality Mammomat Novation syngo-based acquisition workstation, OpView can be used with the MammoReport workstation, which incorporates computer-aided detection (CAD) markers from various vendors.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
